Idelalisib: A Rare Cause of Enterocolitis
Document Type
Article
Publication Date
1-1-2016
Description
Idelalisib is an oral, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, approved by FDA since July 2014 for the treatment of relapsed follicular B-cell non-Hodgkin lymphoma. Data from three phases of the study involving idelalisib demonstrate diarrhea (47%) to be the common adverse effect. The other side effects are pyrexia (28%), fatigue (30%), nausea (29%), cough (29%), pneumonia (25%), abdominal pain (26%) and rash (21%). The characteristic histological findings of idelalisib colitis include intraepithelial lymphocytosis, neutrophilic cryptitis and epithelial cell apoptosis within the crypts. Histological findings help differentiate among other causes of diarrhea and entero-colitis. We present a female patient with recurrent follicular lymphoma treated with idelalisib and presented with diarrhea. She was found to have entero-colitis and was treated successfully with drug discontinuation and prednisone.
Citation Information
Balagoni, Harika; Chaudhari, Dhara; Reddy, Chakradhar; and Young, Mark. 2016. Idelalisib: A Rare Cause of Enterocolitis. Annals of Gastroenterology. Vol.29(2). 233-235. https://doi.org/10.20524/aog.2016.0022 ISSN: 1108-7471
